Aptus-backed neurodegenerative-focused company Alzheon has withdrawn its second attempt at initial public offering, less than year after cancelling its first bid.
Alzheon, a US-based neurodegenerative disorder treatment developer backed by pharmaceutical firm Aptus Therapeutics, has withdrawn its second attempt at an initial public offering on the Nasdaq Global Market.
The company was initially looking to raise approximately $40m in its second IPO attempt after setting the price range between $15 and $16m in August 2018, but shortly after lowered the target to $30m at a price range of $4 to $6.
Proceeds from the second attempt would have been less than…
